<DOC>
	<DOCNO>NCT01911078</DOCNO>
	<brief_summary>The purpose clinical investigation determine effect renal sympathetic denervation insulin resistance muscle sympathetic nerve activity patient metabolic syndrome .</brief_summary>
	<brief_title>Renal Sympathetic Denervation Metabolic Syndrome ( Metabolic Syndrome Study )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<criteria>Patient office blood pressure ≥140/90 mmHg 24hour ambulatory blood pressure ≥130/80 mmHg Baseline despite stable use least two antihypertensive drug maximum tolerated dos patient least 4 week Patient fast glucose ≥100 mg/dL ( ≥5.6 mmol/L ) Baseline drug treatment elevate glucose Patient waist circumference ≥102 cm ( ≥40 inch ) male ≥88 cm ( ≥35 inch ) female Baseline Patient remain two metabolic syndrome diagnostic criterion list follow Baseline Triglycerides ≥150 mg/dL ( ≥1.7 mmol/L ) drug treatment elevate triglyceride High density lipid cholesterol ( HDLC ) &lt; 40 mg/dL ( &lt; 1.03 mmol/L ) male &lt; 50 mg/dL ( &lt; 1.30 mmol/L ) female drug treatment reduce HDLC Patient ≥18 ≤70 year old Patient must able willing provide write informed consent participate clinical investigation Patient must able willing comply require followup schedule Patient secondary hypertension Patient type I diabetes mellitus type II diabetes mellitus require insulin therapy Patient prior renal angioplasty , renal denervation , indwell renal stent and/or aortic stent graft Patient renal artery &lt; 4.0 mm diameter Patient significant renovascular abnormality ( renal artery stenosis &gt; 30 % ) Patient estimate glomerular filtration rate ( eGFR ) &lt; 45 mL/min per 1.73 m2 use Modified Diet Renal Disease ( MDRD ) formula Patient hemodynamically significant valvular heart disease , determine Study Investigator Patient myocardial infarction , unstable angina pectoris cerebrovascular accident le 180 day Baseline expect cardiovascular intervention within next 180 day Patient chronic atrial fibrillation/flutter severe conduction abnormality implantable cardioverter defibrillator ( ICD ) pacemaker whose setting allow radiofrequency ( RF ) energy delivery Patient currently treat drug cause salt retention ( systemic corticosteroid fludrocortisone ) , centrally act sympatholytic antihypertensive drug , direct vasodilator ( alpha blocker ) continuous positive airway pressure ( CPAP ) therapy obstructive sleep apnea Patient active systemic infection bloodclotting abnormality allergy radiographic contrast Patient pregnant childbearing potential use adequate contraceptive method nurse Patient participate another clinical investigation Patient life expectancy le 12 month , determine Study Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Metabolic syndrome</keyword>
	<keyword>Renal denervation</keyword>
	<keyword>Renal artery</keyword>
	<keyword>Muscle sympathetic nerve activity</keyword>
</DOC>